[贝伐单抗（阿瓦斯汀）]

[Bevacizumab (Avastin)].

作者信息

Shimoyama Tatsu

机构信息

Dept. of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital.

出版信息

Gan To Kagaku Ryoho. 2009 Mar;36(3):523-30.

PMID:19295286

Abstract

Vascular endothelial growth factor(VEGF)is a key mediator in angiogenesis, an essential step in tumor growth and metastasis. Elevated levels of VEGF observed in solid tumors are correlated with worse clinical outcomes. Research has therefore focused on developing agents that target VEGF to inhibit tumor growth. Bevacizumab(Avastin), a recombinant humanized monoclonal antibody targeting VEGF. Bevacizumab with conventional chemotherapy has shown antitumor activity in several cancer types with acceptable toxicity. In April 2007, the Japanese Ministry of Health, Labour and Welfare approved bevacizumab for patients with unresectable colorectal cancer.

摘要

血管内皮生长因子（VEGF）是血管生成的关键介质，而血管生成是肿瘤生长和转移的重要步骤。实体瘤中观察到的VEGF水平升高与较差的临床结果相关。因此，研究集中在开发靶向VEGF以抑制肿瘤生长的药物。贝伐单抗（阿瓦斯汀）是一种靶向VEGF的重组人源化单克隆抗体。贝伐单抗与传统化疗联合已在几种癌症类型中显示出抗肿瘤活性，且毒性可接受。2007年4月，日本厚生劳动省批准贝伐单抗用于不可切除的结直肠癌患者。